At the Shenzhen Stock Exchange 2026 Global Investors Conference, SZSE director Chang Shayan said the exchange’s ChiNext board—China’s earliest specialized board established to support technological innovation—has, after 16 years of reform and development, grown to 1,398 listed companies with a combined market capitalization exceeding 21 trillion yuan. High‑technology enterprises account for about 90% of listings and strategic emerging‑industry companies about 70%. Chang said ChiNext has attracte

At a May 28 regular press briefing, the Ministry of Natural Resources published and explained the Guiding Opinions on Accelerating High-Quality Development of Marine Drugs and Functional Products. On intellectual property protection, Yu Jiangyong, deputy director of the Drugs Registration Management Department at the National Medical Products Administration (NMPA), said the NMPA and the China National Intellectual Property Administration (CNIPA) have established an early-resolution mechanism for drug patent disputes. The newly revised Implementing Regulations of the PRC Drug Administration Law (the Regulations) further strengthen protection for drug trial data and establish a market exclusivity-period system for pediatric medicines and drugs for rare diseases. The Measures for the Protection of Drug Trial Data took effect simultaneously with the Regulations on May 15, and the Regulations’ specific implementation documents for the market exclusivity system are currently being intensively drafted. NMPA said these measures will further bolster IP protection for innovative drugs and stimulate firms’ innovation momentum in marine drug R&D.

美国至5月22日当周EIA天然气库存将于十分钟后公布。